FORTRESS BIOTECH INC. - COMMON STOCK

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

06 Jan 2025 08:00:04 By Nasdaq GlobeNewswire

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

14 Nov 2024 16:10:31 By Nasdaq GlobeNewswire

Fortress Biotech to Participate in October 2024 Investor Conferences

26 Sep 2024 08:30:50 By Nasdaq GlobeNewswire

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

20 Sep 2024 08:30:35 By Nasdaq GlobeNewswire

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

04 Sep 2024 08:30:11 By Nasdaq GlobeNewswire

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

13 Aug 2024 16:05:46 By Nasdaq GlobeNewswire

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

25 Jul 2024 08:30:53 By Nasdaq GlobeNewswire

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

05 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Fortress Biotech to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase

16 May 2024 08:00:38 By Nasdaq GlobeNewswire

Fortress Biotech Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

15 May 2024 16:15:29 By Nasdaq GlobeNewswire

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

14 May 2024 08:30:00 By Nasdaq GlobeNewswire

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

28 Mar 2024 16:05:13 By Nasdaq GlobeNewswire